Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biological development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    220 result(s) found for: Biological development. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001341-12 Sponsor Protocol Number: UV/AP/21 Start Date*: 2023-04-14
    Sponsor Name:Red Andaluza de Diseño y Traslación en Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud M.P.
    Full Title: Phase I-II, Multicenter, Randomized, Controlled, Proof of Concept Clinical Trial to determine feasibility, safety and efficacy of the use of Allogenic adipose-derived adult mesenchymal stem cells e...
    Medical condition: Venous ulcer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10047259 Venous ulcer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014491-21 Sponsor Protocol Number: Start Date*: 2009-12-17
    Sponsor Name:Cambridge University Hospitals NHS Trust
    Full Title: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy.
    Medical condition: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005688-32 Sponsor Protocol Number: CD-FNB Start Date*: 2009-07-02
    Sponsor Name:Univeristy Hospital Na Bulovce
    Full Title: Biological therapy in the prevention of Crohn`s disease recurrence after resection in ileocecal region.
    Medical condition: Prevention of Crohn`s disease recurrence after surgery in ileocecal region by postoperative application of infliximab (four infusions).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003806-18 Sponsor Protocol Number: IC2014-16 Start Date*: 2016-03-24
    Sponsor Name:INSTITUT CURIE
    Full Title: IMPROVEMENT OF LOCAL CONTROL IN SKULL BASE AND SPINE CHORDOMAS TREATED BY SURGERY AND PROTONTHERAPY TARGETING HYPOXIC CELLS REVEALED BY POSITRON EMISSION TOMOGRAPHY NITROIMIDAZOLE ([18F]FAZA) PET/C...
    Medical condition: Chordomas of the skull base, spine and sacrum
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002356-37 Sponsor Protocol Number: VAX-TRES Start Date*: 2021-09-22
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica (FCRB)
    Full Title: Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination
    Medical condition: COVID19 vaccine in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015679-28 Sponsor Protocol Number: RHM CHI0499 Start Date*: 2010-09-29
    Sponsor Name:Southampton University Hospitals Trust
    Full Title: PRIMARY PREVENTION OF ATOPY AND ASTHMA WITH ALLERGEN SUBLINGUAL IMMUNOTHERAPY
    Medical condition: Development of atopy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019857 Hereditary allergy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023277-19 Sponsor Protocol Number: Start Date*: 2011-05-05
    Sponsor Name:Med. Univ. Wien, Univ. Klinik für Dermatologie
    Full Title: CD20-Immunotargeting in Stage IV Melanoma Patients- A Prospective, Open Label, Two-Period Pilot Study to Evaluate Overall Tumor Responsive Rate
    Medical condition: Patients suffering from early stage melanoma have a good chance of recovery whereas the 5-year survival rate of patients with metastasized melanomas (stage III and stage IV) is less than 10% for th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012350-20 Sponsor Protocol Number: MSC-KTx Start Date*: 2008-01-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: MESENCHYMAL STEM CELLS UNDER BASILIXIMAB/ LOW DOSE RATG TO INDUCE RENAL TRANSPLANT TOLERANCE
    Medical condition: Patients will be those receiving a living-related kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001671-32 Sponsor Protocol Number: STS-BDB001-04 Start Date*: 2020-05-28
    Sponsor Name:Staidson (Beijing) Biopharmaceutical Co., Ltd. and Beijing Defengrui Biological Technology Co., Ltd.
    Full Title: A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000363-28 Sponsor Protocol Number: GBI001 Start Date*: 2006-10-03
    Sponsor Name:Greater Glasgow Health Board [...]
    1. Greater Glasgow Health Board
    2. Glasgow University
    Full Title: DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS
    Medical condition: Rheumatoid arthritis and Psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001694-14 Sponsor Protocol Number: CYD08 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001711-40 Sponsor Protocol Number: CYD24 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005493-11 Sponsor Protocol Number: CHPAU2014/01 Start Date*: 2015-08-31
    Sponsor Name:Centre Hospitalier de Pau
    Full Title: Intrathecal Rituximab in Progressive Multiple Sclerosis
    Medical condition: Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002781-21 Sponsor Protocol Number: CO11/9730 Start Date*: 2012-02-02
    Sponsor Name:Leeds Teaching Hospitals
    Full Title: A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ...
    Medical condition: Hepatitis C Virus infection - genotype 1. Genotype 1 is least responsive to current treatment and is the focus of this study. HCV can cause severe liver damage - this study will only recruit those ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002123-11 Sponsor Protocol Number: HUIS-04-2020 Start Date*: 2020-05-07
    Sponsor Name:Tatiana Cobo Ibáñez [...]
    1. Tatiana Cobo Ibáñez
    2. Gemma María Mora Ortega
    3. Gonzalo Serralta San Martín
    Full Title: EFFICACY OF CYCLOSPORINE IN THE TREATMENT OF COVID-19 PNEUMONIA: A RANDOMIZED CONTROLLED TRIAL.
    Medical condition: COVID-19 PNEUMONIA
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004193-41 Sponsor Protocol Number: 35RC14_9179 Start Date*: 2014-12-12
    Sponsor Name:CHU de Rennes
    Full Title: Development of a tool for adapting dosage of fluoroquinolones by using a population pharmacokinetic model
    Medical condition: pharmacokinetics of fluoroquinolones
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000540-14 Sponsor Protocol Number: HIGHCARE Start Date*: 2008-05-20
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Role of the renin-angiotensin system in the cardiovascular, metabolic, neurologic and respiratory response to hypobaric hypoxia during sustained exposure to high altitude.
    Medical condition: This study is aimed at the investigation of adaptative physiological mechanisms at high altitude and not at the development of new therapeutic indications.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005295-32 Sponsor Protocol Number: TRALIS001 Start Date*: 2006-02-01
    Sponsor Name:Research and Development Department, Addenbrookes NHS Foundation Trust
    Full Title: Trial in rheumatoid arthritis of lisinopril (TRALIS)
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:48:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA